• Applied Tropifexor (LJN452) Workflows for Intestinal Barrier

  2026-07-17

  Tropifexor (LJN452) stands out as a next-generation FXR agonist for evaluating barrier function and metabolic pathways in both cell-based and animal models. Its exceptional potency, stability, and versatility—when leveraged through optimized protocols—enable reproducible insights into intestinal and hepatic disease mechanisms.

• ACE2 Peptidase Activity: Defining Substrate Specificity and

  2026-07-16

  This study provides a detailed characterization of ACE2 peptidase activity, revealing how specific angiotensin peptide sequences affect ACE2-mediated substrate conversion. By clarifying which angiotensin derivatives serve as the most effective natural substrates, the research advances understanding of RAAS regulation and informs experimental design for studies on vascular, metabolic, and antiviral mechanisms.

• CFDA SE Cell Tracer Kit: Practical Guidance for Stable Cell

  2026-07-16

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit provides durable, covalent fluorescent labeling for long-term cell tracking and proliferation studies with minimal cytotoxicity. It is best suited for applications requiring persistent labeling, and is not appropriate for reversible or short-term cell marking workflows.

• Oligomycin A: Redefining Mitochondrial Checkpoints in Transl

  2026-07-15

  This thought-leadership article explores how Oligomycin A, a gold-standard mitochondrial ATP synthase inhibitor, is catalyzing new frontiers in mitochondrial bioenergetics research, apoptosis pathway study, and cancer metabolism research. By synthesizing the latest mechanistic insights—including evidence from sodium-induced energy collapse pathways—and bridging these with experimental and translational imperatives, we provide researchers with actionable strategies to unlock the next era of therapeutic innovation. APExBIO’s Oligomycin A (SKU A5588) is spotlighted for its unique enabling role in dissecting tumor cell metabolism and immunometabolic checkpoints, with practical guidance for optimizing research workflows.

• Microglial H3K18 Lactylation Protects White Matter After ICH

  2026-07-15

  This study uncovers the neuroprotective role of microglial H3K18 lactylation in white matter injury and cognitive recovery following intracerebral hemorrhage (ICH). By dissecting lactate-driven epigenetic regulation, the research demonstrates that inhibiting this pathway—rather than metabolic lactate generation alone—worsens white matter outcomes, highlighting a potentially targetable axis for brain repair.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer to P

  2026-07-14

  Mei et al. demonstrate that hyperthermia-induced reduction of BRCA2 protein levels markedly increases the sensitivity of BRCA2-proficient ovarian carcinoma cells to PARP inhibition. This mechanistic insight suggests a viable strategy to extend the benefits of PARP inhibitors to patients with BRCA2-proficient tumors, addressing an important clinical challenge in ovarian cancer management.

• ATRX Loss Sensitizes High-Grade Glioma to PDGFR Inhibition

  2026-07-14

  The referenced study demonstrates that ATRX-deficient high-grade glioma cells are particularly vulnerable to receptor tyrosine kinase and PDGFR inhibitors. This finding suggests ATRX status could inform precision therapy and clinical trial design in glioma, with implications for optimizing targeted treatment strategies.

• HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio

  2026-07-13

  This study reveals that HOXC8, a transcription factor overexpressed in non-small cell lung carcinoma (NSCLC), prevents pyroptotic cell death by repressing caspase-1 expression through HDAC1/2-mediated chromatin regulation. These findings illuminate a novel tumor-promoting mechanism in lung cancer and provide new directions for targeted research on the caspase signaling pathway.

• EZ Cap EGFP mRNA 5-moUTP: Advancing mRNA Delivery and Imagin

  2026-07-13

  EZ Cap™ EGFP mRNA (5-moUTP) redefines mRNA delivery for gene expression with robust, sustained fluorescent protein output and minimal immune activation. Its innovative Cap 1 structure and 5-moUTP modifications streamline both in vitro and in vivo workflows, making it the benchmark choice for translation efficiency, imaging, and immune-evasive reporting.

• Morin: Applied Use-Cases and Protocols for Bench Research

  2026-07-12

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) stands out as a multi-functional research tool, bridging disease modeling, antioxidant assays, and fluorescent ion detection. This guide translates its molecular mechanisms into stepwise workflows and troubleshooting strategies, enabling reproducible results across diabetes, neuroprotection, and advanced bioanalytical studies.

• EZ Cap™ Human PTEN mRNA (ψUTP): Mechanisms & Benchmarks

  2026-07-10

  EZ Cap™ Human PTEN mRNA (ψUTP) is an in vitro transcribed mRNA engineered for superior stability and translation of the human PTEN tumor suppressor gene. This reagent leverages Cap1 structure and pseudouridine modifications to enhance protein expression while minimizing innate immune activation, providing a robust tool for cancer research and PI3K/Akt pathway inhibition.

• Ibrexafungerp Activity Against Echinocandin-Resistant Candid

  2026-07-09

  This study rigorously evaluates ibrexafungerp's in vitro efficacy against a large cohort of echinocandin-resistant Candida isolates, highlighting its unique profile among antifungals targeting 1,3-β-D-glucan synthase. The findings inform antifungal selection strategies for resistant infections, with implications for translational research and protocol design.

• Capsazepine: Advanced Insights on TRPV1 Antagonism and Apopt

  2026-07-09

  Explore Capsazepine as a potent TRPV1 ion channel antagonist, with an in-depth focus on its mechanistic roles in nociception inhibition and apoptosis sensitization. This article uniquely connects bench research to translational assay design for pain and oncology studies.

• Multi-Omics Reveals ARID1A-Driven Resistance in Melanoma

  2026-07-08

  This study leverages integrative multi-omics to map drug response networks and uncover how ARID1A loss in BRAF-mutant melanoma drives resistance to BRAF/MAPK inhibition. The findings highlight transcriptional rewiring, altered immune evasion, and identify actionable resistance nodes, informing new therapeutic strategies.

• AL-8810: Redefining Prostaglandin F2α Antagonism in Translat

  2026-07-08

  This thought-leadership article explores the evolving landscape of prostaglandin F2α (PGF2α) signaling research, focusing on AL-8810 as a transformative tool for dissecting FP receptor-mediated mechanisms. Integrating mechanistic insights, recent translational breakthroughs, and strategic guidance, we chart a roadmap for investigators leveraging AL-8810 to unravel vascular and endometrial dynamics and their implications for reproductive and vascular biology.

17080 records 2/1139 page Previous Next 12345 下5页 Last page